Full text is available at the source.
American journal of kidney diseases : the official journal of the National Kidney Foundation···
Comparison of Different Diabetes Drugs Acting on GLP-1 Receptors and Their Effects on Kidney Health in Type 2 Diabetes
Updated
Abstract
Semaglutide was associated with an 8% and 12% reduced risk for the secondary kidney composite outcome compared to dulaglutide and exenatide, respectively.
- No differences were observed among dulaglutide, exenatide, liraglutide, and semaglutide for the primary kidney outcome.
- Semaglutide initiation was associated with a lower risk of death compared to dulaglutide (HR 0.81 [95% CI, 0.70-0.93]).
- The secondary kidney composite outcome included elements such as chronic kidney disease stages 3-4, kidney failure, and death from any cause.
- The findings may indicate that semaglutide could be more effective than other GLP-1 receptor agonists in improving kidney outcomes.
Simplified
RATIONALE & OBJECTIVE: Glucagon-like peptide-1 (GLP-1) receptor agonist treatment is associated with lower risk for incident chronic kidney disease (CKD) and death relative to treatment with a dipeptidyl peptidase-4 inhibitor or sulfonylurea. This study examined within class effects of GLP-1 receptor agonists on kidney outcomes in type 2 diabetes (T2D) and moderate cardiovascular risk.
STUDY DESIGN: Retrospective observational study using the target trial emulation framework.
SETTING & PARTICIPANTS: This study used claims data from OptumLabs® Data Warehouse and 100% sample of Medicare fee-for-service claims. Participants were adults ≥21 years of age, at moderate cardiovascular risk, who filled a new prescription for a GLP-1 receptor agonists between January 1, 2019 and December 31, 2021.
EXPOSURE: GLP-1 receptor agonists dulaglutide, exenatide, liraglutide, or semaglutide.
OUTCOMES: A primary kidney composite outcome inclusive of incident diagnosis codes for CKD stages 3-4 and kidney failure (inclusive of CKD stage 5 and kidney replacement therapy). A secondary kidney composite outcome included the elements of the primary composite outcome plus death from any cause. Components of the kidney composite outcomes were also evaluated independently.
ANALYTICAL APPROACH: Random treatment assignment was emulated using inverse probability of treatment weighting (IPTW) with propensity scores estimated using the SuperLearner ensemble method. Primary analyses were time-to-event models under the intention-to-treat framework using cause-specific IPTW Cox proportional hazards models.
RESULTS: There was no difference among dulaglutide, exenatide, liraglutide, and semaglutide with respect to the primary outcome. When compared to dulaglutide and exenatide, semaglutide was associated with a reduced risk for the secondary kidney composite outcome by 8% (HR 0.92 [95% CI, 0.87-0.97]) and 12% (HR:0.88; 95% CI: 0.79-0.99), respectively. Compared to dulaglutide, semaglutide was also associated with reduced risk of death (HR 0.81 [95% CI, 0.70-0.93]).
LIMITATIONS: Potential for residual confounding, lack of HbA1c and weight data, and uncertainty about the indication for GLP-1 receptor agonist prescriptions.
CONCLUSIONS: No differences were observed among different GLP-1 receptor agonists for the primary outcome, but semaglutide initiation was associated with a lower risk of the secondary kidney composite outcome and of death.
PLAIN-LANGUAGE SUMMARY: Chronic kidney disease (CKD) is a common complication of diabetes that increases the risk for poor health outcomes. Glucagon-like peptide-1 (GLP-1) receptor agonists were found to improve kidney outcomes in people with type 2 diabetes (T2D) and moderate cardiovascular risk when compared to dipeptidyl peptidase-4 inhibitors and sulfonylureas. While there has been no head-to-head comparison of individual GLP-1 receptor agonists, randomized controlled trials suggest that there may be variation among members of this drug class on kidney disease outcomes. In this study, we tested whether there were differences in kidney outcomes when comparing individual GLP-1 receptor agonist medications. We found that semaglutide compared favorably to other drugs in the class and may represent the preferred GLP-1 receptor agonist for delaying or preventing CKD in this population.
Related papers
Dec '24
Kidney health in type 2 diabetes with moderate heart risk using four common diabetes medicines
top 5% journal
cited by 5 papers
journal article
Feb '25
GLP-1 receptor drugs for people with diabetes and long-term kidney disease
cited by 10 papers
systematic review
Aug '25
Risk of Serious Diabetic Eye Disease with Common Diabetes Drugs Semaglutide, Dulaglutide, Liraglutide, and Exenatide in Everyday Care
top 5% journal
cited by 2 papers
multicenter study
Oct '25
Comparing Liraglutide, Semaglutide, and Dulaglutide in Veterans with Type 2 Diabetes
top 2% journal
cited by 5 papers
comparative study
Mar '24
Real-World Effects of Weekly GLP-1 Medicines Compared to DPP-4 Inhibitors on Blood Sugar and Weight in Type 2 Diabetes
top 30% journal
cited by 8 papers
observational study
Sep '25
How GLP-1 drugs compare in heart health for adults with type 2 diabetes and moderate heart risk
top 10% journal
cited by 5 papers
comparative study
Nov '25
Glucagon-like Peptide-1 Receptor Agonists and Risk of Major Heart Problems in People with Chronic Kidney Disease
top 5% journal
journal article
Jan '25
Kidney and heart health in chronic kidney disease patients taking GLP-1 receptor agonists
top 5% journal
cited by 32 papers
systematic review
Feb '26
Leg and foot problems in adults with type 2 diabetes using four common diabetes medicines: a trial-like comparison
top 20% journal
journal article
May '25
Glucagon-like peptide-1 drugs vs. sodium/glucose transporter inhibitors for reducing kidney failure and death in type 2 diabetes patients with kidney disease
top 5% journal
cited by 6 papers
comparative study